Graft Polymer (UK) PLC ( (GB:SVNS) ) has shared an update.
Solvonis Therapeutics plc has appointed Dr. Renata Crome as a Non-Executive Director, bringing over 40 years of experience in pharmaceutical development and commercialization. Her expertise in CNS, oncology, and infectious diseases, along with her leadership in developing blockbuster drugs, aligns with Solvonis’s focus on mental health and addiction therapies, potentially enhancing the company’s strategic direction and industry positioning.
More about Graft Polymer (UK) PLC
Solvonis Therapeutics plc is an innovative biotechnology company focused on developing intellectual property related to the treatment of mental health and substance use disorders, and co-developing therapeutics for mental health disorders. The company aims to improve outcomes for individuals suffering from mental health disorders, with an initial focus on trauma-related mental health conditions, such as PTSD.
YTD Price Performance: -22.50%
Average Trading Volume: 13,002,774
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £3.56M
For a thorough assessment of SVNS stock, go to TipRanks’ Stock Analysis page.